サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1629907

プレフィルドシリンジの世界市場-2025～2033年

Global Pre-Filled Syringes Market - 2025-2033

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
プレフィルドシリンジの世界市場-2025～2033年
出版日: 2024年12月30日
発行: DataM Intelligence
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

プレフィルドシリンジの世界市場は、2023年に86億5,606万米ドルに達し、2033年には300億4,262万米ドルに達すると予測され、予測期間2025年にはCAGR 15.5%で成長すると予測されています。

プレフィルドシリンジは、あらかじめ計量された薬やワクチンの量が入った、すぐに使える医療機器です。これらの注射器にはあらかじめ一定量の薬剤が充填されているため、ヘルスケア専門家や患者にとって便利です。プレフィルドシリンジは通常、シリンジバレル、プランジャー、注射針または注射針シールドから構成されます。プレフィルドシリンジの中には、使用時や廃棄時の安全性を高めるために、針シールドや開閉式針などの安全機能が付いているものもあります。プレフィルドシリンジは、環境要因から薬剤を保護することができるため、従来の薬剤包装に比べ、保存期間が長い場合が多いです。

セルフケアの台頭は、ヘルスケア市場におけるプレフィルドシリンジの需要促進に大きな役割を果たしています。人々が健康管理においてより積極的な役割を担うようになり、薬の自己投与はますます一般的になってきています。例えば、米国国立衛生研究所（NIH）が実施した研究によると、合計234人の患者がアンケートに回答し、半数（50％）の患者が自己投薬に前向きでした。しかし、看護師による服薬管理よりも自己管理を希望した患者は37％に過ぎませんでした。プレフィルドシリンジはユーザーフレンドリーなソリューションを提供し、複雑な投薬量測定の必要性をなくし、個人の服薬自己管理を容易にします。また、ハーバード大学によると、プレフィルドシリンジは世界中で年間70億本使用されています。

市場力学：

促進要因と阻害要因

自己注射の人気上昇

自己注射の人気の高まりがプレフィルドシリンジ市場の成長を大きく後押ししており、予測期間中も市場を牽引していくとみられます。自己注射により、患者は自宅で快適に薬を注射することができ、これは糖尿病、関節リウマチ、多発性硬化症などの慢性疾患にとって特に重要です。この利便性により、頻繁な通院の必要性が減少するため、患者とヘルスケア提供者の双方にとって時間とコストの節約となります。

例えば、米国国立衛生研究所（NIH）が実施した研究によると、糖尿病研究患者の大多数（62％）はインスリンの自己注射に好意的でした。177人（72.2％）の大多数がインスリンを自己注射した経験がありますが、45度で適切にインスリンを注入した患者は120人（49.0％）に過ぎませんでした。

国際糖尿病連合によると、2035年の糖尿病患者数は5億9,200万人に達すると推定されています。同様に、エチオピアでは180万人以上の糖尿病患者がおり、成人人口の全国有病率は4.36％でした。このような糖尿病の増加により、インスリンの自己注射の需要が高まり、プレフィルドシリンジの需要も増加しています。

在宅ヘルスケアサービスの成長は、セルフケアの動向と密接に結びついています。プレフィルドシリンジは在宅ヘルスケアのモデルに適しており、患者は頻繁に病院や診療所を訪れることなく必要な治療を受けることができます。遠隔医療や遠隔モニタリング技術の利用が増加しており、セルフケア介入をサポートしています。プレフィルドシリンジはバーチャル診察で処方することができ、ヘルスケアプロバイダーは患者の経過を遠隔監視し、必要に応じて治療計画の指導や調整を行うことができます。

また、WHOによると、世界人口の5人に1人が人道的危機の中で生活していると推定されており、このような状況では医療システムは必要不可欠なサービスを提供することが困難です。セルフケア介入は、保健ワーカーの支援の有無にかかわらず、個人、家族、地域社会が健康を促進し、病気を予防し、健康を維持し、病気や障害に対処する能力を支援する手段です。

限られた薬剤容量

プレフィルドシリンジの薬剤容量には限りがあるため、特に複雑で大容量の薬剤では、その有用性を制限するいくつかの課題があり、市場成長の妨げになると予想されます。プレフィルドシリンジは通常、バイアルや他の包装形態に比べて薬剤容量が小さいです。そのため、特定の用量を必要とする医薬品への使用が制限されます。多くのプレフィルドシリンジは1回投与用に設計されており、総容量は1～2mLに制限されています。

例えば、Diabetes Journals Organizationによると、インスリンシリンジには0.3、0.5、1.0mLのサイズがあり、それぞれ30、50、100単位のインスリンを入れることができます。インスリンプレフィルドシリンジは、注射器の容量の制約から、最大投与量は約1.0mLに制限されています。これは、より大量投与が必要な薬剤には十分ではないかもしれません。

多くの生物学的製剤や高濃度の薬剤は、効果的な治療のためにより大きな容量を必要としますが、プレフィルドシリンジは容量が限られているため、必ずしも適切ではありません。この課題は、効能を維持するために高濃度・高容量が必要とされるがん領域で使用される薬剤で特に顕著です。例えば、市販されているプレフィルドシリンジの大半は2mLまでの容量ですが、モノクローナル抗体や高濃度の生物製剤のような薬剤には十分ではないかもしれません。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • 製品別スニペット
  • 素材別スニペット
  • デザイン別スニペット
  • 用途別スニペット
  • エンドユーザー別スニペット
  • 地域別スニペット

第3章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病の罹患率の上昇
      • 技術の進歩の高まり
    • 抑制要因
      • データプライバシーに関する懸念
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名なプレーヤー
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 プレフィルドシリンジ市場、製品別

  • ニードルフリープレフィルドシリンジ
  • ニードル付きプレフィルドシリンジ

第6章 プレフィルドシリンジ市場、素材別

  • ガラス製プレフィルドシリンジ
  • プラスチック製プレフィルドシリンジ

第7章 プレフィルドシリンジ市場、デザイン別

  • シングルチャンバーPFS
  • デュアルチャンバーPFS

第8章 プレフィルドシリンジ市場、用途別

  • 糖尿病
  • 関節リウマチ
  • 眼科
  • アナフィラキシー
  • その他

第9章 プレフィルドシリンジ市場、エンドユーザー別

  • 病院・クリニック
  • 外来手術センター
  • その他

第10章 プレフィルドシリンジ市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場プレーヤー
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第12章 企業プロファイル

  • Becton, Dickinson, and Company
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Gerresheimer AG
  • Schott AG
  • Stevanato Group S.p.A.
  • Terumo Corporation
  • Sanofi S.A.
  • Hikma Pharmaceuticals PLC
  • MedXL Inc.
  • West Pharmaceutical Services, Inc.
  • Cardinal Health

第13章 仮定と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第14章 付録

目次
Product Code: MD692

The global pre-filled syringes market reached US$ 8656.06 million in 2023 and is expected to reach US$ 30042.62 million by 2033, growing at a CAGR of 15.5% during the forecast period 2025-2033.

Pre-filled syringes are ready-to-use medical devices containing a pre-measured medication or vaccine dose. These syringes come pre-loaded with a specific amount of a drug, making them convenient for healthcare professionals and patients. The pre-filled syringe typically consists of a syringe barrel, a plunger, and a needle or a needle shield. Some pre-filled syringes come with safety features, such as needle shields or retractable needles, to enhance safety during use and disposal. Pre-filled syringes often have a longer shelf life compared to some traditional forms of medication packaging, as they can protect the drug from environmental factors.

The rise of self-care interventions has played a significant role in driving the demand for pre-filled syringes in the healthcare market. Self-administration of medications is becoming increasingly common as people take a more active role in managing their health. For instance, according to the Study conducted by the National Institute of Health (NIH), in total, 234 patients completed the questionnaire. Half (50%) of the patients were willing to self-administer medication. However, only 37% of patients preferred self-administration of medication over nurse-led medication administration. Pre-filled syringes offer a user-friendly solution, eliminating the need for complex dosage measurements and making it easier for individuals to self-administer their medications. Additionally, according to Harvard University, 7 billion prefilled syringes are used annually around the world.

Market Dynamics: Drivers & Restraints

Rising popularity of self-administration

The rising popularity of self-administration is significantly driving the growth of the pre-filled syringes market and is expected to drive the market over the forecast period. Self-administration allows patients to inject medications in the comfort of their homes, which is particularly important for chronic conditions such as diabetes, rheumatoid arthritis and multiple sclerosis. This convenience reduces the need for frequent hospital visits, thus saving time and costs for both patients and healthcare providers.

For instance, according to the study conducted by the National Institute of Health (NIH), the majority (62%) of the diabetes study patients had a favorable attitude toward insulin self-administration. Although the majority of 177(72.2%) of the study patients have administered insulin themselves, only 120(49.0%) of the patients injected insulin appropriately at 45 degrees.

According to the International Diabetes Federation estimated that diabetes reach 592 million in the year 2035. Similarly, there were more than 1.8 million diabetes patients in Ethiopia with a national prevalence of 4.36% among the adult population. This rising diabetes increases the demand for insulin self-administration, which in turn increases the demand for prefilled syringes.

The growth of home healthcare services is closely tied to the self-care trend. Pre-filled syringes fit well within the home healthcare model, allowing patients to receive necessary treatments without the need for frequent hospital or clinic visits. The increasing use of telemedicine and remote monitoring technologies supports self-care interventions. Pre-filled syringes can be prescribed during virtual consultations, and healthcare providers can remotely monitor patients' progress, offering guidance and adjustments to treatment plans as needed.

Additionally, according to WHO, estimated that 1 in 5 of the world's population are now living in humanitarian crises, in which health systems are challenged to deliver essential services. Self-care interventions are tools that support the ability of individuals, families and communities to promote health, prevent disease, maintain health, and cope with illness and disability with or without the support of a health worker.

Limited drug capacity

The limited drug capacity of pre-filled syringes is expected to hamper the growth of the market due to several challenges that restrict their utility, especially for complex and large-volume drugs. Pre-filled syringes typically have a smaller drug capacity compared to vials and other packaging formats. This restricts their use of medications with specific dosage requirements. Many pre-filled syringes are designed for single-dose applications, often limiting the total volume to 1 to 2 mL.

For instance, according to the Diabetes Journals Organization, insulin syringes come in different sizes, including 0.3, 0.5 and 1.0 mL sizes that hold up to 30, 50, and 100 units of insulin, respectively. Insulin pre-filled syringes are limited to a maximum dose of around 1.0 mL due to syringe capacity constraints. This may not be sufficient for medications requiring larger doses.

Many biologics and high-concentration drugs require larger volumes for effective treatment, but pre-filled syringes are not always suitable due to limited capacity. The challenge is particularly pronounced with drugs used in oncology, where high concentrations and volumes are needed to maintain efficacy. For instance, the majority of pre-filled syringes on the market can hold up to 2 mL, which might not be sufficient for drugs like monoclonal antibodies and high-concentration biologics.

Segment Analysis

The global pre-filled syringes market is segmented based on product, material, design, application, end-user and region.

Product Type:

The needled prefilled syringes segment is expected to dominate the pre-filled syringes market share

Needled pre-filled syringes are widely used for a range of applications, including insulin administration, vaccines and biologic therapies. Insulin and diabetes management are prime examples, where pre-filled syringes equipped with needles provide a reliable and convenient method for daily self-administration. Needled pre-filled syringes are preferred for their ability to deliver drugs directly into the bloodstream, ensuring effective therapeutic outcomes. The presence of a needle allows for precise dosing, which is crucial for biologics and therapies requiring targeted delivery.

For instance, in September 2024, BD (Becton, Dickinson and Company) released the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak Glass Prefillable Syringe platform to serve the growing market for biologic therapies. This solution features an 8-millimeter needle length and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity. The BD Neopak Glass Prefillable Syringe platform is designed to address key development needs for biologic drugs.

Advanced safety mechanisms integrated into needled pre-filled syringes improve their safety profile. These features have become essential in healthcare settings, especially for hospital administrations, and for patient safety. For instance, in August 2024, Schreiner MediPharm introduced Needle-Trap Secu, a protection label with a newly integrated seal function that enhances sustainability and cost efficiency in the storage, transportation and disposal of prefilled syringes. Its compact design technology effectively protects against needlestick injuries while saving space and resources.

Geographical Analysis

North America is expected to hold a significant position in the pre-filled syringes market share

There is a growing trend towards self-administration in North America especially in the United States, driven by the convenience it offers to patients and caregivers. Self-injection pens and needled pre-filled syringes are widely used for managing chronic conditions like diabetes, rheumatoid arthritis, and multiple sclerosis. For instance, the National Institute of Health reports indicate that in the United States, approximately 40% of the population self-medicates, this further boosts the demand for prefilled syringes in the region.

North America is a major market for biologics and biosimilars, which are primarily delivered using pre-filled syringes. The growing prevalence of chronic diseases and the increasing adoption of biologics for treatment have driven the demand for pre-filled syringes in the region. For instance, according to the Pharmaceutical Research and Manufacturers of America, as of the end of 2022, 40 biosimilars have been approved and there are 27 biosimilars on the market in the U.S. competing against ten brand biologics with several more scheduled to launch throughout 2023.

Asia-Pacific is growing at the fastest pace in the Pre-Filled Syringes market

Rapidly improving healthcare infrastructure across countries like China, India, Japan, South Korea, and others in the APAC region is driving the adoption of advanced medical devices like pre-filled syringes. Investments in healthcare facilities, government initiatives to improve access to quality healthcare, and the establishment of specialized hospitals and clinics are boosting the demand for pre-filled syringes. For instance, in China, the government's healthcare reforms have led to increased spending on healthcare infrastructure, which is accelerating the adoption of advanced drug delivery systems such as pre-filled syringes.

For instance, in June 2022, WuXi Biologics launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. The DP5 is the ninth operational drug product facility in the global network of WuXi Biologics. The DP5 facility features an isolator filling line for continuous and steady filling services, which offers multiple volume delivery options for pre-filled syringes (PFS), including 1 mL Long, 1 mL, 2.25 mL and 3 mL, notes WuXi. The maximum filling speed reportedly can reach 400 PFS/min to support 17 million syringes of drug products manufacturing every year.

The rising prevalence of chronic diseases such as diabetes, cardiovascular diseases and cancer in the APAC region is a major driver. These diseases often require long-term treatment regimens, making pre-filled syringes a convenient and preferred method of drug delivery. For instance, China has one of the highest numbers of diabetes patients, currently having 140.9 million people with diabetes, which is set to increase to 174.4 million by 2045., driving the demand for insulin-pre-filled syringes

Competitive Landscape

The major global players in the pre-filled syringes market include Becton, Dickinson, and Company, Gerresheimer AG, Schott AG, Stevanato Group S.p.A., Terumo Corporation, Sanofi S.A., Hikma Pharmaceuticals PLC, MedXL Inc., West Pharmaceutical Services, Inc., Cardinal Health and among others.

Key Developments

  • In September 2024, BD (Becton, Dickinson and Company) announced the commercial release of the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak Glass Prefillable Syringe platform to serve the growing market for biologic therapies.
  • In March 2024, Biocon Biologics, a subsidiary of Biocon, on Monday officially announced a settlement with Bayer and Regeneron Pharmaceuticals. This agreement allows Biocon Biologics to launch Yesafili, a proposed biosimilar to EYLEA (aflibercept) Injection, in the Canadian market. Under the terms of the company agreement, Biocon Biologics has secured a launch date for Yesafili 2 mg New Drug Submission (NDS) for vials and prefilled syringes, with the launch set up to July 1, 2025.
  • In January 2023, Schreiner MediPharm presented a security label for syringes at Pharmapack Paris in early February. Met with ample interest among eventgoers, the company's Syringe-Closure-Wrap is a multifunctional label for pre-filled syringes that provides a clear first-opening indication, enabling the detection of previous use, tampering or counterfeiting attempts.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global pre-filled syringes market report delivers a detailed analysis with 78 key tables, more than 71 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product
  • 2.4. Snippet by Material
  • 2.5. Snippet by Design
  • 2.6. Snippet by Application
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Data Privacy Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Pre-Filled Syringes Market, By Product

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 5.1.2. Market Attractiveness Index, By Product
  • 5.2. Needle Free Prefilled Syringes*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Needled Prefilled Syringes

6. Pre-Filled Syringes Market, By Material

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 6.1.2. Market Attractiveness Index, By Material
  • 6.2. Glass Prefilled Syringes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Plastic Prefilled Syringes

7. Pre-Filled Syringes Market, By Design

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 7.1.2. Market Attractiveness Index, By Design
  • 7.2. Single Chambered PFS*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Dual Chambered PFS

8. Pre-Filled Syringes Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Diabetes*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Rheumatoid Arthritis
  • 8.4. Ophthalmology
  • 8.5. Anaphylaxis
  • 8.6. Others

9. Pre-Filled Syringes Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals & Clinics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Others

10. Pre-Filled Syringes Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. Becton, Dickinson, and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. Gerresheimer AG
  • 12.3. Schott AG
  • 12.4. Stevanato Group S.p.A.
  • 12.5. Terumo Corporation
  • 12.6. Sanofi S.A.
  • 12.7. Hikma Pharmaceuticals PLC
  • 12.8. MedXL Inc.
  • 12.9. West Pharmaceutical Services, Inc.
  • 12.10. Cardinal Health

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us